134 related articles for article (PubMed ID: 1388279)
1. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset.
Carey GJ; Costall B; Domeney AM; Gerrard PA; Jones DN; Naylor RJ; Tyers MB
Pharmacol Biochem Behav; 1992 May; 42(1):75-83. PubMed ID: 1388279
[TBL] [Abstract][Full Text] [Related]
2. The effects of ondansetron, a 5-HT3 receptor antagonist, on cognition in rodents and primates.
Barnes JM; Costall B; Coughlan J; Domeney AM; Gerrard PA; Kelly ME; Naylor RJ; Onaivi ES; Tomkins DM; Tyers MB
Pharmacol Biochem Behav; 1990 Apr; 35(4):955-62. PubMed ID: 2140610
[TBL] [Abstract][Full Text] [Related]
3. The effect of ondansetron on cognitive performance in the marmoset.
Domeney AM; Costall B; Gerrard PA; Jones DN; Naylor RJ; Tyers MB
Pharmacol Biochem Behav; 1991 Jan; 38(1):169-75. PubMed ID: 1826787
[TBL] [Abstract][Full Text] [Related]
4. Dose-related impairment of spatial learning by intrahippocampal scopolamine: antagonism by ondansetron, a 5-HT3 receptor antagonist.
Carli M; Luschi R; Samanin R
Behav Brain Res; 1997 Jan; 82(2):185-94. PubMed ID: 9030400
[TBL] [Abstract][Full Text] [Related]
5. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys.
Arnsten AF; Lin CH; Van Dyck CH; Stanhope KJ
Neurobiol Aging; 1997; 18(1):21-8. PubMed ID: 8983029
[TBL] [Abstract][Full Text] [Related]
6. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T
Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task.
Bratt AM; Kelly ME; Domeney AM; Naylor RJ; Costall B
Neuroreport; 1994 Oct; 5(15):1921-4. PubMed ID: 7841377
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of the 5-HT3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system.
Hodges H; Sowinski P; Turner JJ; Fletcher A
Psychopharmacology (Berl); 1996 May; 125(2):146-61. PubMed ID: 8783389
[TBL] [Abstract][Full Text] [Related]
9. Different effects of tropisetron and ondansetron in learning and memory paradigms.
Pitsikas N; Borsini F
Pharmacol Biochem Behav; 1997 Apr; 56(4):571-6. PubMed ID: 9130279
[TBL] [Abstract][Full Text] [Related]
10. Flumazenil and tacrine increase the effectiveness of ondansetron on scopolamine-induced impairment of spatial learning in rats.
Diez-Ariza M; Redondo C; García-Alloza M; Lasheras B; Del Río J; Ramírez MJ
Psychopharmacology (Berl); 2003 Aug; 169(1):35-41. PubMed ID: 12845416
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron amelioration of scopolamine induced cognitive deficits in three-panel runway apparatus in rats.
Kumar N; Kela AK
Indian J Exp Biol; 2004 Sep; 42(9):919-21. PubMed ID: 15462187
[TBL] [Abstract][Full Text] [Related]
12. The effect of several putative cognition enhancers on a water maze acquisition deficit produced by pCPA + scopolamine combination treatment.
Harder JA; Kelly ME
Pharmacol Biochem Behav; 1997 Apr; 56(4):657-61. PubMed ID: 9130291
[TBL] [Abstract][Full Text] [Related]
13. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.
Schechter LE; Smith DL; Rosenzweig-Lipson S; Sukoff SJ; Dawson LA; Marquis K; Jones D; Piesla M; Andree T; Nawoschik S; Harder JA; Womack MD; Buccafusco J; Terry AV; Hoebel B; Rada P; Kelly M; Abou-Gharbia M; Barrett JE; Childers W
J Pharmacol Exp Ther; 2005 Sep; 314(3):1274-89. PubMed ID: 15951399
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the muscarinic antagonist effects of scopolamine and L-687,306.
Winger G; Jutkiewicz EM; Woods JH
Behav Pharmacol; 2020 Jun; 31(4):359-367. PubMed ID: 31922966
[TBL] [Abstract][Full Text] [Related]
15. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats.
de Bruin NM; Prickaerts J; van Loevezijn A; Venhorst J; de Groote L; Houba P; Reneerkens O; Akkerman S; Kruse CG
Neurobiol Learn Mem; 2011 Sep; 96(2):392-402. PubMed ID: 21757018
[TBL] [Abstract][Full Text] [Related]
16. Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methysergide or alaproclate.
Riekkinen P; Sirviö J; Riekkinen P
Psychopharmacology (Berl); 1991; 103(4):567-70. PubMed ID: 1829538
[TBL] [Abstract][Full Text] [Related]
17. 5-HT3 receptors in selective animal models of cognition.
Sridhar N; Veeranjaneyulu A; Arulmozhi DK; Gupta CN; Babu RJ
Indian J Exp Biol; 2002 Feb; 40(2):174-80. PubMed ID: 12622180
[TBL] [Abstract][Full Text] [Related]
18. Effect of DAU 6215, a novel 5-HT3 receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task.
Pitsikas N; Brambilla A; Borsini F
Pharmacol Biochem Behav; 1994 Jan; 47(1):95-9. PubMed ID: 8115433
[TBL] [Abstract][Full Text] [Related]
19. The dopamine D3/D2 receptor agonist 7-OH-DPAT induces cognitive impairment in the marmoset.
Smith AG; Neill JC; Costall B
Pharmacol Biochem Behav; 1999 Jun; 63(2):201-11. PubMed ID: 10371648
[TBL] [Abstract][Full Text] [Related]
20. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
Lieben CK; Blokland A; Sik A; Sung E; van Nieuwenhuizen P; Schreiber R
Neuropsychopharmacology; 2005 Dec; 30(12):2169-79. PubMed ID: 15957009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
